Cargando…
One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032067/ https://www.ncbi.nlm.nih.gov/pubmed/35456268 http://dx.doi.org/10.3390/jcm11082175 |
_version_ | 1784692549115445248 |
---|---|
author | Kitagawa, Yorihisa Shimada, Hiroyuki Mori, Ryusaburo Tanaka, Koji Wakatsuki, Yu Onoe, Hajime Kaneko, Hiroyuki Machida, Yumiko Nakashizuka, Hiroyuki |
author_facet | Kitagawa, Yorihisa Shimada, Hiroyuki Mori, Ryusaburo Tanaka, Koji Wakatsuki, Yu Onoe, Hajime Kaneko, Hiroyuki Machida, Yumiko Nakashizuka, Hiroyuki |
author_sort | Kitagawa, Yorihisa |
collection | PubMed |
description | This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this treatment modality in PCV patients was conducted in 64 patients (64 eyes). Early Treatment Diabetic Retinopathy Study (ETDRS) score, central retinal thickness (CRT), and central pigment epithelial detachment thickness (CPEDT) before and 1, 3, and 12 months after treatment were analyzed. Mean ETDRS score increased from 58 at baseline to 64 letters (p = 0.0122), CRT decreased from 543 to 192 μm (p < 0.0001), and CPEDT decreased from 161 to 103 μm (p = 0.0668) at 3 months and were maintained until 12 months. Complications requiring reoperation occurred within one month in four eyes. Recurrence was observed in 46 eyes (72%), and 1.6 ± 1.5 (0–7) intravitreal aflibercept injections were given pro re nata. Univariate and multivariate analyses identified CPEDT as the pre- and post-treatment factor affecting 12-month ETDRS score (p < 0.0001). Improved visual acuity stabilized 3 months after treatment. Although 72% of patients experienced recurrence, an average of 1.6 aflibercept injections/patient maintained visual acuity up to 12 months. CPEDT was the most important factor associated with visual outcome. |
format | Online Article Text |
id | pubmed-9032067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90320672022-04-23 One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy Kitagawa, Yorihisa Shimada, Hiroyuki Mori, Ryusaburo Tanaka, Koji Wakatsuki, Yu Onoe, Hajime Kaneko, Hiroyuki Machida, Yumiko Nakashizuka, Hiroyuki J Clin Med Article This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this treatment modality in PCV patients was conducted in 64 patients (64 eyes). Early Treatment Diabetic Retinopathy Study (ETDRS) score, central retinal thickness (CRT), and central pigment epithelial detachment thickness (CPEDT) before and 1, 3, and 12 months after treatment were analyzed. Mean ETDRS score increased from 58 at baseline to 64 letters (p = 0.0122), CRT decreased from 543 to 192 μm (p < 0.0001), and CPEDT decreased from 161 to 103 μm (p = 0.0668) at 3 months and were maintained until 12 months. Complications requiring reoperation occurred within one month in four eyes. Recurrence was observed in 46 eyes (72%), and 1.6 ± 1.5 (0–7) intravitreal aflibercept injections were given pro re nata. Univariate and multivariate analyses identified CPEDT as the pre- and post-treatment factor affecting 12-month ETDRS score (p < 0.0001). Improved visual acuity stabilized 3 months after treatment. Although 72% of patients experienced recurrence, an average of 1.6 aflibercept injections/patient maintained visual acuity up to 12 months. CPEDT was the most important factor associated with visual outcome. MDPI 2022-04-13 /pmc/articles/PMC9032067/ /pubmed/35456268 http://dx.doi.org/10.3390/jcm11082175 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kitagawa, Yorihisa Shimada, Hiroyuki Mori, Ryusaburo Tanaka, Koji Wakatsuki, Yu Onoe, Hajime Kaneko, Hiroyuki Machida, Yumiko Nakashizuka, Hiroyuki One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy |
title | One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy |
title_full | One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy |
title_fullStr | One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy |
title_full_unstemmed | One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy |
title_short | One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy |
title_sort | one-year outcome of intravitreal tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage in polypoidal choroidal vasculopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032067/ https://www.ncbi.nlm.nih.gov/pubmed/35456268 http://dx.doi.org/10.3390/jcm11082175 |
work_keys_str_mv | AT kitagawayorihisa oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT shimadahiroyuki oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT moriryusaburo oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT tanakakoji oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT wakatsukiyu oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT onoehajime oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT kanekohiroyuki oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT machidayumiko oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy AT nakashizukahiroyuki oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy |